Emerging role of long non‑coding RNAs in pulmonary hypertension and their molecular mechanisms (Review)

Qin, Yuhan; Yan, Gaoliang; Ye, Qiao; Wang, Dong; Luo, Erfei; Hou, Jiantong; Tang, Chengchun

doi:10.3892/etm.2020.9293

Cited by 5 publications

(4 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An animal or cellular model of hypoxia is the basis for the majority of the lncRNAs discussed previously in the article. Furthermore, utilizing the tissues of PAH patients, other lncRNAs, such as Lnc-Ang362, PAXIP1-AS1, MEG3, and MALAT1, have been investigated [ 133 ]. One need to supplement is idiopathic PAH (IPAH), IPAH patients are essentially PAH patients, and research has revealed a close relationship between lncRNAs and iPAH.…”

Section: Molecular Mechanism Of Lncrnas In Phmentioning

confidence: 99%

Roles of LncRNAs in the Pathogenesis of Pulmonary Hypertension

Liu,

Xu,

Yang

et al. 2024

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Pulmonary hypertension (PH) is a persistently progressive, incurable, multifactorial associated fatal pulmonary vascular disease characterized by pulmonary vascular remodeling. Long noncoding RNAs (lncRNAs) are involved in regulating pathological processes such as pulmonary vasoconstriction, thickening, remodeling, and inflammatory cell infiltration in PH by acting on different cell types. Because of their differential expression in PH patients, as demonstrated by the observation that some lncRNAs are significantly upregulated while others are significantly downregulated in PH patients, lncRNAs are potentially useful biomarkers for assessing disease progression and diagnosis or prognosis in PH patients. This article provides an overview of the different mechanisms by which lncRNAs are involved in the pathogenesis of PH.

show abstract

Section: Molecular Mechanism Of Lncrnas In Phmentioning

confidence: 99%

Roles of LncRNAs in the Pathogenesis of Pulmonary Hypertension

Liu,

Xu,

Yang

et al. 2024

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Currently, the molecular mechanisms of lncRNA in PAH mainly focus on proliferation, migration and apoptosis of pulmonary artery smooth muscle cells and dysfunction of pulmonary artery endothelial cells [42]. The mechanism of action of lncRNA-TCONS_00008552 was not explored further because the sequence, structure and function of lncRNAs are poorly conserved across species.…”

Section: Plos Onementioning

confidence: 99%

lncRNA-TCONS_00008552 expression in patients with pulmonary arterial hypertension due to congenital heart disease

Yang¹,

Fan²,

Lai³

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are potential regulators of a variety of cardiovascular diseases. Therefore, there is a series of differentially expressed lncRNAs in pulmonary arterial hypertension (PAH) that may be used as markers to diagnose PAH and even predict the prognosis. However, their specific mechanisms remain largely unknown. Therefore, we investigated the biological role of lncRNAs in patients with PAH. First, we screened patients with PAH secondary to ventricular septal defect (VSD) and those with VSD without PAH to assess differences in lncRNA and mRNA expression between the two groups. Our results revealed the significant upregulation of 813 lncRNAs and 527 mRNAs and significant downregulation of 541 lncRNAs and 268 mRNAs in patients with PAH. Then, we identified 10 hub genes in a constructed protein-protein interaction network. Next, we performed bioinformatics analyses, including Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis and subsequently constructed coding-noncoding co-expression networks. We screened lncRNA-TCONS_00008552 and lncRNA-ENST00000433673 as candidate genes and verified the expression levels of the lncRNAs using quantitative reverse-transcription PCR. Although expression levels of lncRNA-TCONS_00008552 in the plasma from the PAH groups were significantly increased compared with the control groups, there was no significant difference in the expression of lncRNA-ENST00000433673 between the two groups. This study bolsters our understanding of the role of lncRNA in PAH occurrence and development and indicates that lncRNA-TCONS_00008552 is a novel potential molecular marker for PAH.

show abstract

“…The functional and mechanistic role of PASMCs in the development of PH is still largely unknown. Only few lncRNAs have been investigated in endothelial cells of PH, while the majority of lncRNA studies have concentrated on their regulatory role of the PASMCs during the development of PH [ 33 , 71 , 72 , 73 ]. LncRNA functionality is dependent on subcellular localization, which is critical in understanding lncRNA interaction partners, mechanism and translational potential [ 27 ].…”

Section: Long Noncoding Rnas (Lncrnas) In Pulmonary Hypertensionmentioning

confidence: 99%

The Landscape of Noncoding RNA in Pulmonary Hypertension

et al. 2022

View full text Add to dashboard Cite

The transcriptome of pulmonary hypertension (PH) is complex and highly genetically heterogeneous, with noncoding RNA transcripts playing crucial roles. The majority of RNAs in the noncoding transcriptome are long noncoding RNAs (lncRNAs) with less circular RNAs (circRNAs), which are two characteristics gaining increasing attention in the forefront of RNA research field. These noncoding transcripts (especially lncRNAs and circRNAs) exert important regulatory functions in PH and emerge as potential disease biomarkers and therapeutic targets. Recent technological advancements have established great momentum for discovery and functional characterization of ncRNAs, which include broad transcriptome sequencing such as bulk RNA-sequence, single-cell and spatial transcriptomics, and RNA-protein/RNA interactions. In this review, we summarize the current research on the classification, biogenesis, and the biological functions and molecular mechanisms of these noncoding RNAs (ncRNAs) involved in the pulmonary vascular remodeling in PH. Furthermore, we highlight the utility and challenges of using these ncRNAs as biomarkers and therapeutics in PH.

show abstract

Emerging role of long non‑coding RNAs in pulmonary hypertension and their molecular mechanisms (Review)

Cited by 5 publications

References 110 publications

Roles of LncRNAs in the Pathogenesis of Pulmonary Hypertension

Roles of LncRNAs in the Pathogenesis of Pulmonary Hypertension

lncRNA-TCONS_00008552 expression in patients with pulmonary arterial hypertension due to congenital heart disease

The Landscape of Noncoding RNA in Pulmonary Hypertension

Contact Info

Product

Resources

About